Piloting Treatment With Intranasal Oxytocin in Phelan-McDermid Syndrome

Status Completed

Clinical Trial Summary

This is a pilot study examining the efficacy, safety and tolerability of intranasal oxytocin as a novel treatment in Phelan-McDermid syndrome (PMS). This study will utilize a randomized, placebo-controlled design for 12 weeks (phase 1), followed by an open-label extension for 12 weeks (phase 2). The purpose is to evaluate the effect of intranasal oxytocin on impairments in attention, social memory, socialization, language, and repetitive behaviors.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02710084
Study type	Interventional
Source	Icahn School of Medicine at Mount Sinai
Contact
Status	Completed
Phase	Phase 2
Start date	April 29, 2016
Completion date	July 29, 2020

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT03836300` - Parent and Infant Inter(X)Action Intervention (PIXI)	N/A
Completed	`NCT03493607` - AMO-01 to Treat Adolescents and Adults With Phelan-McDermid Syndrome (PMS) and Co-morbid Epilepsy	Phase 2
Completed	`NCT03426059` - Mapping the Phenotype in Adults With Phelan-McDermid Syndrome
Recruiting	`NCT02461420` - Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
Completed	`NCT02000167` - Mitochondrial Dysfunction in Phelan-McDermid Syndrome
Enrolling by invitation	`NCT04312152` - Q10 Ubiquinol in Autism Spectrum Disorder and in Phelan-McDermid Syndrome.	N/A
Completed	`NCT05105685` - Effectiveness of Recombinant Human Growth Hormone Therapy for Children With PMS	Phase 1/Phase 2
Enrolling by invitation	`NCT05187377` - A Controlled Trial of Growth Hormone in Phelan-McDermid Syndrome and Idiopathic Autism	Phase 2
Completed	`NCT01525901` - Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)	Phase 2
Active, not recruiting	`NCT05025241` - An Open-Label Study of Oral NNZ-2591 in Phelan-McDermid Syndrome (PMS-001)	Phase 2